BioNTech SE is 1.3x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($21.79 B vs $16.17 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | BNTX |
|---|---|---|
| Market cap | $16.17 B | $21.79 B |
| US-listed rank | #700 | #587 |
| Revenue (latest FY) | $2.86B | - |
| Net income (latest FY) | $478.60M | - |
| Net margin | 16.7% | - |
| P/E (trailing FY) | 33.8 | - |
| SEC filings | 2,097 | 548 |
BioNTech SE is 1.3x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($21.79 B vs $16.17 B).
Full pages: NEUROCRINE BIOSCIENCES INC and BioNTech SE, or browse the full rankings.